证券代码：688098 证券简称：申联生物 公告编号：2025-040 一、本次解除冻结的股份原冻结情况 股东 UBI 所持公司 1,815,221 股股份存在被司法冻结的情形，内容详见公司 于 2019 年 12 月 5 日在上海证券交易所网站（www.sse.com.cn）披露的《申联生 物医药(上海)股份有限公司关于持股 5%以上股东股份被司法冻结的公告》（公 告编号：2019-008）。 股东 UBI 被法院强制执行被动减持公司股份 730,000 股，内容详见公司于 2023 年 3 月 23 日在上海证券交易所网站（www.sse.com.cn）披露的《申联生物 医药(上海)股份有限公司持股 5%以上股东部分股份被动减持的公告》（公告编 号：2023-004）。2023 年 3 月 30 日，股东 UBI 被法院强制执行被动减持公司股 份 4,000 股作为前述事项执行费，因此 UBI 持有的公司股份冻结数量为 1,081,221 股。 申联生物医药(上海)股份有限公司 关于持股 5%以上股东所持股份解除冻结的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏， ...

申联生物医药（上海）股份有限公司 简式权益变动报告书 证券代码：688098 证券简称：申联生物 申联生物医药（上海）股份有限公司 简式权益变动报告书 上市公司：申联生物医药（上海）股份有限公司 股票上市地：上海证券交易所 股票简称：申联生物 股票代码：688098 信息披露义务人：UNITED BIOMEDICAL,INC. 住所：25 Davids Drive Hauppauge, NY 11788, USA 通讯地址：25 Davids Drive Hauppauge, NY 11788, USA 股份变动性质：股份减少 签署日期：2025 年 11 月 28 日 申联生物医药（上海）股份有限公司 简式权益变动报告书 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司收购管理办法》（以下简称"《收购办法》"）、《公开发行证券的公 司信息披露内容与格式准则第 15 号—权益变动报告书》（以下简称"《准则 15 号》"）及相关的法律、法规编写本报告书。 二、信息披露义务人签署本报告已获得必要的授权和批准，其履行亦不违反 信息披露义务人章程或内部规则中的 ...

证券代码：688098 证券简称：申联生物 公告编号：2025-041 申联生物医药（上海）股份有限公司 关于持股 5%以上股东权益变动触及 5%整数倍的 提示性公告 信息披露义务人美国联合生物医药公司保证向本公司提供的信息真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性和完整性依法承担 法律责任。本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 一、 信息披露义务人及其一致行动人的基本信息 2.信息披露义务人信息 | 信息披露义务人名称 | 投资者身份 | 统一社会信用代码 | | --- | --- | --- | | □ | 控股股东/实控人 | | | 美国联合生物医药公 □ | 控股股东/实控人的一致 | □ _____________ | | 司 | 行动人 | 不适用 ☑ | | | ☑ 其他直接持股股东 | | 二、 权益变动触及 5%整数倍的基本情况 公司于近日收到美国联合生物医药公司（UNITED BIOMEDICAL, INC.以下 简称"UBI"）出具的《UBI 关于权益变动触及 5%整数倍的告知函》，本次权益 变动后信息披露义务人合计持有 ...

Core Viewpoint - The company received a notification from United BioPharma regarding a planned share reduction through centralized bidding from November 24 to 28, 2025, which will decrease the shareholder's stake from 10.52% to 10.00% [1] Summary by Relevant Sections - **Shareholder Action** - The shareholder will reduce their holdings by selling shares, resulting in a total of 41,064,498 shares held post-reduction [1] - **Impact on Company** - The reduction does not violate any commitments, does not trigger mandatory tender offer obligations, and will not lead to changes in the company's controlling shareholder or actual controller [1] - The operational impact on the company is deemed minimal [1]

Core Viewpoint - UNITEDBIOMEDICAL, INC. has reduced its shareholding in the company by 2.1354 million shares, representing 0.52% of the total share capital, due to its own funding needs, without affecting the actual control of the company or harming the interests of the company and other shareholders [1] Summary by Relevant Sections - Shareholding Reduction - UNITEDBIOMEDICAL, INC. sold a total of 2.1354 million shares from November 24 to November 28, 2025 [1] - Post-reduction, UNITEDBIOMEDICAL, INC. holds 41.0645 million shares, which is 10.00% of the total share capital [1] - The previous shareholding percentage was 10.52% [1]

Group 1 - The company, Shenlian Bio, reported that as of September 30, 2025, the total number of common stock shareholders is 12,388 [1]

Core Viewpoint - The animal health sector experienced a slight decline of 0.2% on November 24, with *ST Lvkang leading the drop [1][2] Market Performance - The Shanghai Composite Index closed at 3836.77, up 0.05% - The Shenzhen Component Index closed at 12585.08, up 0.37% [1] Individual Stock Performance - Notable gainers in the animal health sector included: - Shenlian Biological (688098) with a closing price of 9.57, up 2.57% on a trading volume of 55,100 shares and a turnover of 52.32 million yuan - Yongshun Biological (920729) at 8.95, up 1.59% with a trading volume of 15,900 shares and a turnover of 14.22 million yuan - Xianfeng Holdings (002141) at 3.98, up 1.53% with a trading volume of 694,200 shares and a turnover of 275 million yuan [1] Capital Flow Analysis - The animal health sector saw a net outflow of 35.49 million yuan from institutional investors, while retail investors contributed a net inflow of 31.36 million yuan [2][3] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [3] Stock-Specific Capital Flow - Key stocks with significant capital flow include: - Dayu Biological (920970) with a net inflow of 1.55 million yuan from institutional investors - Pulaike (603566) with a net inflow of 0.99 million yuan from institutional investors - Shenlian Biological (688098) faced a net outflow of 2.88 million yuan from institutional investors [3]

Core Viewpoint - The animal health sector experienced a significant decline of 4.0% on November 21, with Shunlian Biological leading the drop [1] Market Performance - The Shanghai Composite Index closed at 3834.89, down 2.45% - The Shenzhen Component Index closed at 12538.07, down 3.41% [1] Individual Stock Performance - Shunlian Biological (688098) closed at 9.33, down 5.85% with a trading volume of 58,100 shares and a turnover of 55.30 million yuan - Huisheng Biological (300871) closed at 19.33, down 5.71% with a trading volume of 65,400 shares and a turnover of 130 million yuan - Yongshun Biological (920729) closed at 8.81, down 5.47% with a trading volume of 23,700 shares and a turnover of 21.71 million yuan - *ST Green Health (002868) closed at 41.88, down 4.99% with a trading volume of 5,569 shares and a turnover of 23.32 million yuan - Biological Shares (600201) closed at 11.76, down 4.85% with a trading volume of 491,800 shares [1] Capital Flow Analysis - The animal health sector saw a net outflow of 128 million yuan from institutional investors, while retail investors had a net inflow of 87.82 million yuan [1] - The following stocks had notable capital flows: - Shunlian Biological: net outflow of 11.71 million yuan from institutional investors [2] - *ST Green Health: net outflow of 6.34 million yuan from institutional investors, but a net inflow of 990,000 yuan from retail investors [2] - Huisheng Biological: net outflow of 8.69 million yuan from institutional investors, with a net inflow of 432,630 yuan from retail investors [2]

Core Viewpoint - The animal health sector experienced a slight decline of 0.31% on November 19, with Xianfeng Holdings leading the losses, while the Shanghai Composite Index rose by 0.18% to close at 3946.74 [1]. Group 1: Market Performance - The animal health sector's individual stock performance varied, with notable gainers including Qudongli (up 3.98% to 10.71) and ST Lvkang (up 3.80% to 46.40) [1]. - Conversely, several stocks faced declines, such as Jinhai Biological (down 0.96% to 6.19) and Shunlian Biological (down 1.08% to 10.12) [1][2]. Group 2: Trading Volume and Capital Flow - The total trading volume for the animal health sector was significant, with Qudongli achieving a volume of 34,000 hands and a transaction value of approximately 35.9 million yuan [1]. - The sector saw a net outflow of 49.13 million yuan from institutional investors, while retail investors contributed a net inflow of 548.09 million yuan [2]. Group 3: Individual Stock Capital Flow - Among individual stocks, Shengong Holdings experienced a net outflow of 31.56 million yuan from retail investors, while Biotech Holdings saw a net inflow of 555.72 million yuan from retail investors [3]. - The stock with the highest net inflow from retail investors was Biotech Holdings, with 555.72 million yuan, while the largest net outflow was from Yongshun Biological, totaling 408.61 million yuan [3].

Core Insights - The animal health sector experienced a decline of 0.24% on November 17, with Dayu Biological leading the drop [1] - The Shanghai Composite Index closed at 3972.03, down 0.46%, while the Shenzhen Component Index closed at 13202.0, down 0.11% [1] Stock Performance - Notable gainers included: - Qudongli (code: 920275) with a closing price of 10.68, up 5.12% [1] - *ST Lvkang (code: 002868) with a closing price of 42.57, up 5.01% [1] - Houfeng Holdings (code: 002141) with a closing price of 3.91, up 2.62% [1] - Major decliners included: - Dayu Biological (code: 920970) with a closing price of 8.70, down 3.87% [2] - Ruipu Biological (code: 300119) with a closing price of 20.61, down 2.92% [2] - Zhongmu Co., Ltd. (code: 600195) with a closing price of 7.94, down 1.98% [2] Capital Flow - The animal health sector saw a net outflow of 10.15 million yuan from institutional investors, while retail investors experienced a net outflow of 20.76 million yuan [2] - Conversely, speculative funds recorded a net inflow of 30.91 million yuan [2] Individual Stock Capital Flow - Notable capital flows included: - Biological Shares (code: 600201) with a net inflow of 12.08 million yuan from institutional investors [3] - Xianfeng Holdings (code: 002141) with a net inflow of 9.50 million yuan from institutional investors [3] - Ruipu Biological (code: 300119) with a net inflow of 1.05 million yuan from speculative funds [3] - Decliners in capital flow included: - *ST Lvkang (code: 002868) with a net outflow of 0.79 million yuan from institutional investors [3] - Hai Li Biological (code: 603718) with a net outflow of 2.82 million yuan from institutional investors [3]